AEON Biopharma, Inc. (AEON)
NYSEAMERICAN: AEON · Real-Time Price · USD
0.1134
-0.0273 (-19.40%)
At close: Nov 17, 2026, 4:00 PM EST
0.1194
+0.0060 (5.29%)
Pre-market: Nov 18, 2026, 6:53 AM EST
AEON Biopharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
8
Market Cap
5.66M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ensysce Biosciences | 6.19M |
| Immuron | 5.34M |
| Cerenome | 3.53M |
| Vistagen Therapeutics | 2.38M |
| Longeveron | 1.17M |
| Kiora Pharmaceuticals | 1.00M |
| Exicure | 500.00K |
| Soligenix | 2.34K |
AEON News
- 1 day ago - AEON Biopharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 day ago - AEON Biopharma Quarterly report: Q3 2026 - Filings
- 1 day ago - AEON Biopharma Earnings release: Q3 2026 - Filings
- 8 days ago - Aeon submits IND application to the FDA for comparative pharmacodynamic study - TheFly
- 8 days ago - AEON Biopharma Submits IND for Comparative Pharmacodynamic Study of ABP-450 - GlobeNewsWire
- 22 days ago - AEON Biopharma Proxy statement: Proxy filing - Filings
- 27 days ago - AEON Biopharma Slides: Corporate presentation - Filings
- 5 weeks ago - AEON Biopharma Proxy statement: Proxy filing - Filings